---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016717"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2026-05-13T20:05:56+00:00"
generated_at: "2026-05-13T22:08:33.893915+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M

## Summary
- Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
- EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.
- ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.
- Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.
- Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025.

## SEC filing metadata
- accession: 0001437749-26-016717
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2026-05-13T20:05:56+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/0001437749-26-016717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/aytu20260209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016717
- JSON: https://secwatch.observer/filing/0001437749-26-016717.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.